{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:37Z","timestamp":1791300517497,"version":"4.1.0"},"reference-count":188,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2016.00064","type":"journal-article","created":{"date-parts":[[2016,5,20]],"date-time":"2016-05-20T10:03:51Z","timestamp":1463738631000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":123,"title":["Idiopathic Inflammatory Myopathies: Clinical Approach and Management"],"prefix":"10.3389","volume":"7","author":[{"given":"Asma","family":"Malik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazala","family":"Hayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid S.","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2016,5,20]]},"reference":[{"issue":"21","key":"B1","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis, and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"issue":"9388","key":"B2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"issue":"7","key":"B3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"8","key":"B4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"3","key":"B5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/0046-8177(89)90128-7","article-title":"Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies","volume":"20","author":"Emslie-Smith","year":"1989","journal-title":"Hum Pathol"},{"issue":"3","key":"B6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/00019052-199606000-00015","article-title":"The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis","volume":"9","author":"Dalakas","year":"1996","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"B7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N Engl J Med"},{"issue":"0889\u2013857X","key":"B8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0889-857X(21)00074-0","article-title":"Relationship of cancer to inflammatory muscle diseases. Dermatomyositis, polymyositis, and inclusion body myositis","volume":"20","author":"Callen","year":"1994","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"B9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0889-857X(02)00021-2","article-title":"Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria","volume":"28","author":"Mastaglia","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"issue":"3","key":"B10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.coph.2010.03.001","article-title":"Inflammatory muscle diseases: a critical review on pathogenesis and therapies","volume":"10","author":"Dalakas","year":"2010","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"B11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1517\/17530051003713499","article-title":"Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies","volume":"4","author":"Schmidt","year":"2010","journal-title":"Expert Opin Med Diagn"},{"key":"B12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.mayocp.2012.10.017","article-title":"Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations","volume":"88","author":"Ernste","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"B13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"B14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3899\/jrheum.120682","article-title":"Classification, diagnosis, and management of idiopathic inflammatory myopathies","volume":"40","author":"Lazarou","year":"2013","journal-title":"J Rheumatol"},{"issue":"6","key":"B15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","article-title":"Acquired immune and inflammatory myopathies: pathologic classification","volume":"23","author":"Pestronk","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2013-305690","article-title":"Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features","volume":"84","author":"Brady","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"B17","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC International Workshop: Inclusion Body Myositis, 2\u20134 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"B18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"B19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3899\/jrheum.140566","article-title":"Polymyositis\/dermatomyositis and malignancy risk: a metaanalysis study","volume":"42","author":"Yang","year":"2015","journal-title":"J Rheumatol"},{"issue":"6","key":"B20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0002-9343(70)80006-7","article-title":"The epidemiology of polymyositis","volume":"48","author":"Medsger","year":"1970","journal-title":"Am J Med"},{"issue":"3","key":"B21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/08916930600622132","article-title":"Update on idiopathic inflammatory myopathies","volume":"39","author":"Briani","year":"2006","journal-title":"Autoimmunity"},{"issue":"3","key":"B22","first-page":"445","article-title":"Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota","volume":"35","author":"Wilson","year":"2008","journal-title":"J Rheumatol"},{"issue":"5","key":"B23","doi-asserted-by":"publisher","first-page":"A330","DOI":"10.1016\/j.autrev.2009.11.006","article-title":"The geoepidemiology of autoimmune muscle disease","volume":"9","author":"Prieto","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"3","key":"B24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0032-1329201","article-title":"Idiopathic inflammatory myopathies","volume":"32","author":"Dimachkie","year":"2012","journal-title":"Semin Neurol"},{"issue":"5","key":"B25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/mus.23302","article-title":"Epidemiology of adult idiopathic inflammatory myopathies in a U.S. Managed care plan","volume":"45","author":"Furst","year":"2012","journal-title":"Muscle Nerve"},{"issue":"3","key":"B26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1212\/WNL.61.3.316","article-title":"Polymyositis: an overdiagnosed entity","volume":"61","author":"van der Meulen","year":"2003","journal-title":"Neurology"},{"issue":"6","key":"B27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"B28","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1365-2133.2011.10595.x","article-title":"Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study","volume":"165","author":"Kuo","year":"2011","journal-title":"Br J Dermatol"},{"issue":"12","key":"B29","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.jocn.2008.01.011","article-title":"Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis","volume":"15","author":"Needham","year":"2008","journal-title":"J Clin Neurosci"},{"issue":"11","key":"B30","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"issue":"3","key":"B31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/0049-0172(86)90014-4","article-title":"Adult onset polymyositis\/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature","volume":"5","author":"Hochberg","year":"1986","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"B32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0733-8619(05)70337-6","article-title":"Idiopathic inflammatory myopathies","volume":"15","author":"Amato","year":"1997","journal-title":"Neurol Clin"},{"issue":"6","key":"B33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/00002281-199911000-00005","article-title":"Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis","volume":"11","author":"Sontheimer","year":"1999","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"B34","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3949\/ccjm.80a.12171","article-title":"Antisynthetase syndrome: not just an inflammatory myopathy","volume":"80","author":"Chatterjee","year":"2013","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"B35","first-page":"14","article-title":"Scleroderma overlap syndrome","volume":"13","author":"Balbir-Gurman","year":"2011","journal-title":"Isr Med Assoc J"},{"issue":"2","key":"B36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jbspin.2009.08.008","article-title":"Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients","volume":"77","author":"Vancsa","year":"2010","journal-title":"Jt Bone Spine"},{"issue":"1","key":"B37","doi-asserted-by":"publisher","first-page":"124S","DOI":"10.1111\/1523-1747.ep12356896","article-title":"Amyopathic dermatomyositis: a review","volume":"100","author":"Euwer","year":"1993","journal-title":"J Invest Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0889-857X(05)70350-1","article-title":"Classification and treatment of the juvenile idiopathic inflammatory myopathies","volume":"23","author":"Rider","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"B39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pediatrneurol.2011.01.018","article-title":"Idiopathic inflammatory myopathies in childhood: a brief review of 27 cases","volume":"45","author":"Lorenzoni","year":"2011","journal-title":"Pediatr Neurol"},{"issue":"6","key":"B40","first-page":"1198","article-title":"Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children","volume":"25","author":"Pachman","year":"1998","journal-title":"J Rheumatol"},{"issue":"6","key":"B41","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10794","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"47","author":"Marie","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"6","key":"B42","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/00002281-200211000-00006","article-title":"Cardiac involvement in myositis","volume":"14","author":"Yazici","year":"2002","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"B43","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1212\/WNL.41.6.936","article-title":"Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration","volume":"41","author":"Emslie-Smith","year":"1991","journal-title":"Neurology"},{"issue":"4","key":"B44","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s00415-003-1027-y","article-title":"Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy","volume":"250","author":"Bronner","year":"2003","journal-title":"J Neurol"},{"issue":"2","key":"B45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"issue":"6","key":"B46","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/BOR.0b013e32834b324b","article-title":"Necrotizing autoimmune myopathy","volume":"23","author":"Liang","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"Pt 3","key":"B47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"issue":"4","key":"B48","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ana.410400407","article-title":"Inclusion body myositis: clinical and pathological boundaries","volume":"40","author":"Amato","year":"1996","journal-title":"Ann Neurol"},{"key":"B49","first-page":"256","article-title":"Inclusion body myositis: old and new concepts","volume":"80","author":"Sekul","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"issue":"4","key":"B51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","article-title":"Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis","volume":"56","author":"Bohan","year":"1977","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"B52","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/BF02030515","article-title":"Correlation between tests of muscle involvement and clinical muscle weakness in polymyositis and dermatomyositis","volume":"9","author":"Tymms","year":"1990","journal-title":"Clin Rheumatol"},{"issue":"6","key":"B53","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine"},{"issue":"6","key":"B54","first-page":"692","article-title":"Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations","volume":"16","author":"Hengstman","year":"2004","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"B55","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"B56","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"B57","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11926-012-0246-6","article-title":"Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment","volume":"14","author":"Mimori","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"B58","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","article-title":"Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression","volume":"48","author":"Gunawardena","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"B59","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","article-title":"Classification criteria for the idiopathic inflammatory myopathies","volume":"9","author":"Targoff","year":"1997","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"B60","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/BOR.0b013e328358bd85","article-title":"Myositis autoantibodies","volume":"24","author":"Casciola-Rosen","year":"2012","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"B61","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/ard.2006.068502","article-title":"The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis","volume":"66","author":"Chinoy","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"B62","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/art.24547","article-title":"Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis","volume":"60","author":"Gunawardena","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"B63","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-\u03b3 antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology"},{"issue":"4","key":"B64","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","article-title":"Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy","volume":"94","author":"Joffe","year":"1993","journal-title":"Am J Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"issue":"8","key":"B66","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/art.24702","article-title":"Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women","volume":"60","author":"Love","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"7","key":"B67","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.clineuro.2011.12.055","article-title":"Unusual manifestations in two cases of necrotizing myopathy associated with SRP-antibodies","volume":"114","author":"Hanisch","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"B68","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/art.11484","article-title":"Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy","volume":"50","author":"Kao","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"9","key":"B69","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"12","key":"B70","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study","volume":"134","author":"Buchbinder","year":"2001","journal-title":"Ann Intern Med"},{"issue":"9250","key":"B71","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)04588-8","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"B72","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1468-1331.2010.03220.x","article-title":"Screening for tumours in paraneoplastic syndromes: report of an EFNS task force","volume":"18","author":"Titulaer","year":"2011","journal-title":"Eur J Neurol"},{"issue":"4","key":"B73","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000093866","article-title":"Needle electromyographic findings in 98 patients with myositis","volume":"55","author":"Blijham","year":"2006","journal-title":"Eur Neurol"},{"issue":"10","key":"B74","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/jnnp.2008.169375","article-title":"Evaluation and treatment of inflammatory myopathies","volume":"80","author":"Amato","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"B75","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1148\/radiographics.15.3.7624563","article-title":"The idiopathic inflammatory myopathies: spectrum of MR imaging findings","volume":"15","author":"Adams","year":"1995","journal-title":"Radiographics"},{"issue":"6","key":"B76","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.2214\/AJR.08.1764","article-title":"MRI findings in inflammatory muscle diseases and their noninflammatory mimics","volume":"192","author":"Schulze","year":"2009","journal-title":"Am J Roentgenol"},{"issue":"5","key":"B77","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/rheumatology\/keh130","article-title":"Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis","volume":"43","author":"Maillard","year":"2004","journal-title":"Rheumatology"},{"issue":"1","key":"B78","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/art.23248","article-title":"The provisional Paediatric Rheumatology International Trials Organisation\/American College of Rheumatology\/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study","volume":"59","author":"Ruperto","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"12","key":"B79","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00256-010-0930-4","article-title":"Morphologic imaging in muscular dystrophies and inflammatory myopathies","volume":"39","author":"Degardin","year":"2010","journal-title":"Skeletal Radiol"},{"issue":"11","key":"B80","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1212\/01.wnl.0000187124.92826.20","article-title":"Plasma cells in muscle in inclusion body myositis and polymyositis","volume":"65","author":"Greenberg","year":"2005","journal-title":"Neurology"},{"issue":"7","key":"B81","first-page":"BR191","article-title":"cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies","volume":"10","author":"Zhou","year":"2004","journal-title":"Med Sci Monit"},{"issue":"8","key":"B82","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1002\/eji.201040602","article-title":"Accumulation of plasmacytoid DC: roles in disease pathogenesis and targets for immunotherapy","volume":"40","author":"Swiecki","year":"2010","journal-title":"Eur J Immuno"},{"issue":"2","key":"B83","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410160206","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells","volume":"16","author":"Arahata","year":"1984","journal-title":"Ann Neurol"},{"issue":"5","key":"B84","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1002\/art.22558","article-title":"Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis","volume":"56","author":"Lopez De Padilla","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B85","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev.immunol.23.021704.115633","article-title":"IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors","volume":"23","author":"Liu","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"B86","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular deposition of complement membrane attack complex in dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N Engl J Med"},{"issue":"4","key":"B87","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ana.410270402","article-title":"Microvascular changes in early and advanced dermatomyositis: a quantitative study","volume":"27","author":"Emslie-Smith","year":"1990","journal-title":"Ann Neurol"},{"issue":"1","key":"B88","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/mus.21651","article-title":"Vascular pathology in dermatomyositis and anatomic relations to myopathology","volume":"42","author":"Pestronk","year":"2010","journal-title":"Muscle Nerve"},{"issue":"1\u20133","key":"B89","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0022-510X(89)90228-1","article-title":"Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle","volume":"94","author":"De Visser","year":"1989","journal-title":"J Neurol Sci"},{"issue":"6","key":"B90","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/00002281-200311000-00006","article-title":"Skin involvement in dermatomyositis","volume":"15","author":"Santmyire-Rosenberger","year":"2003","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"B91","first-page":"603","article-title":"Cutaneous manifestations of gastrointestinal disorders","volume":"76","author":"Callen","year":"1978","journal-title":"J Ky Med Assoc"},{"issue":"7","key":"B92","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S0046-8177(86)80180-0","article-title":"Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies","volume":"17","author":"Engel","year":"1986","journal-title":"Hum Pathol"},{"key":"B93","first-page":"141","article-title":"Immune effector mechanisms in inflammatory myopathies","volume":"68","author":"Engel","year":"1990","journal-title":"Res Publ Assoc Res Nerv Ment Dis"},{"issue":"1","key":"B94","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/jclinpath-2011-200138","article-title":"Validity of internal expression of the major histocompatibility complex class I in the diagnosis of inflammatory myopathies","volume":"65","author":"Salaroli","year":"2012","journal-title":"J Clin Pathol"},{"issue":"1","key":"B95","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/mus.20649","article-title":"Myeloid dendritic cells in inclusion-body myositis and polymyositis","volume":"35","author":"Greenberg","year":"2007","journal-title":"Muscle Nerve"},{"issue":"5","key":"B96","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"issue":"8","key":"B97","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/ncpneuro0261","article-title":"Sporadic inclusion body myositis \u2013 diagnosis, pathogenesis and therapeutic strategies","volume":"2","author":"Dalakas","year":"2006","journal-title":"Nat Clin Pract Neurol"},{"issue":"1","key":"B98","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ana.21622","article-title":"Sporadic inclusion body myositis: pathogenic considerations","volume":"65","author":"Karpati","year":"2009","journal-title":"Ann Neurol"},{"issue":"8","key":"B99","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/NEN.0b013e31826183c8","article-title":"Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis","volume":"71","author":"Askanas","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"B100","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1750-3639.2009.00290.x","article-title":"Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation: mini-symposium: protein aggregate myopathies","volume":"19","author":"Askanas","year":"2009","journal-title":"Brain Pathol"},{"issue":"4","key":"B101","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/brain\/aws046","article-title":"Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1beta-induced accumulation of? beta-amyloid and cell death","volume":"135","author":"Schmidt","year":"2012","journal-title":"Brain"},{"issue":"6","key":"B102","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","article-title":"Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile","volume":"181","author":"Preu\u00dfe","year":"2012","journal-title":"Am J Pathol"},{"issue":"2","key":"B103","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/mus.22279","article-title":"Necrotizing myopathy: clinicoserologic associations","volume":"45","author":"Ellis","year":"2012","journal-title":"Muscle Nerve"},{"issue":"2","key":"B104","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"391","key":"B105","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF02950398","article-title":"Dermatomyositis successfully treated by prednisone","volume":"33","author":"Micks","year":"1958","journal-title":"Ir J Med Sci"},{"issue":"6","key":"B106","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisone in subacute inflammatory myositis, a randomised clinical trial","volume":"20","author":"van de Vlekkert","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"B107","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1590\/S0482-50042012000400009","article-title":"Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"52","author":"Pereira","year":"2012","journal-title":"Rev Bras Reumatol"},{"issue":"7","key":"B108","first-page":"1729","article-title":"Improved therapeutic index of methotrexate with \u201cleucovorin rescue\u201d","volume":"33","author":"Levitt","year":"1973","journal-title":"Cancer Res"},{"issue":"6","key":"B109","doi-asserted-by":"publisher","first-page":"762.784","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"B110","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1212\/WNL.36.1.35","article-title":"Azathioprine toxicity in neuromuscular disease","volume":"36","author":"Kissel","year":"1986","journal-title":"Neurology"},{"issue":"8","key":"B111","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1200\/JCO.2001.19.8.2293","article-title":"Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine","volume":"19","author":"Evans","year":"2001","journal-title":"J Clin Oncol"},{"issue":"12","key":"B112","doi-asserted-by":"publisher","first-page":"814","DOI":"10.7326\/0003-4819-154-12-201106210-00009","article-title":"Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review","volume":"154","author":"Booth","year":"2011","journal-title":"Ann Intern Med"},{"issue":"7","key":"B113","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nrrheum.2009.103","article-title":"Management of RA medications in pregnant patients","volume":"5","author":"Ostensen","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"19","key":"B114","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"issue":"6 Suppl 5","key":"B115","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1212\/WNL.51.6_Suppl_5.S2","article-title":"Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases","volume":"51","author":"Dalakas","year":"1998","journal-title":"Neurology"},{"issue":"2\u20133","key":"B116","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s12026-013-8408-9","article-title":"Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature","volume":"56","author":"Nalotto","year":"2013","journal-title":"Immunol Res"},{"issue":"3","key":"B117","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1445-5994.2011.02702.x","article-title":"Efficacy of rituximab in refractory antisynthetase syndrome","volume":"42","author":"Limaye","year":"2012","journal-title":"Intern Med J"},{"issue":"9","key":"B118","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/rheumatology\/keu024","article-title":"Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population","volume":"53","author":"Aringer","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"B119","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1136\/jnnp.2006.092353","article-title":"Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis","volume":"77","author":"Vulliemoz","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"B120","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3109\/03009749709065660","article-title":"Cyclosporine treatment for polymyositis\/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis?","volume":"26","author":"Maeda","year":"1997","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"B121","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","author":"Amato","year":"2011","journal-title":"Ann Neurol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"A80","DOI":"10.1136\/ard.2010.149013.31","article-title":"Anakinra effects on T cells in patients with refractory idiopathic inflammatory myopathies","volume":"70","author":"Zong","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B123","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/art.25669","article-title":"Anakinra in patients with refractory idiopathic inflammatory myopathies","volume":"60","author":"Dorph","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"5","key":"B124","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","article-title":"Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up","volume":"73","author":"Zong","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"B125","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"issue":"3","key":"B126","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/rheumatology\/keu484","article-title":"Long-term efficacy of alemtuzumab in polymyositis","volume":"54","author":"Ruck","year":"2015","journal-title":"Meuth Rheumatol (Oxford)"},{"issue":"5","key":"B127","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrd3436","article-title":"Belimumab","volume":"10","author":"Sanz","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"B128","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"B129","first-page":"50","article-title":"Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis","volume":"12","author":"Yoshimasu","year":"2002","journal-title":"Eur J Dermatol"},{"issue":"2","key":"B130","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"B131","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/archdermatol.2011.2052","article-title":"Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009","volume":"148","author":"Balin","year":"2012","journal-title":"Arch Dermatol"},{"issue":"3","key":"B132","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","article-title":"Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis","volume":"160","author":"Arabshahi","year":"2012","journal-title":"J Pediatr"},{"issue":"12","key":"B133","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00415-009-5229-9","article-title":"Detecting dysphagia in inclusion body myositis","volume":"256","author":"Cox","year":"2009","journal-title":"J Neurol"},{"issue":"3","key":"B134","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"issue":"2","key":"B135","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1212\/WNL.58.2.326","article-title":"Intravenous immunoglobulin for dysphagia of inclusion body myositis","volume":"58","author":"Cherin","year":"2002","journal-title":"Neurology"},{"issue":"1","key":"B136","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"issue":"12","key":"B137","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"B138","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00455-011-9384-7","article-title":"Pharyngeal dysphagia in inflammatory muscle diseases resulting from impaired suprahyoid musculature","volume":"27","author":"Langdon","year":"2012","journal-title":"Dysphagia"},{"issue":"4","key":"B139","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4065\/82.4.441","article-title":"Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients","volume":"82","author":"Oh","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"B140","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/PHM.0b013e31818a50e2","article-title":"Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome","volume":"87","author":"Oh","year":"2008","journal-title":"Am J Phys Med Rehabil"},{"issue":"6","key":"B141","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1155\/2004\/360537","article-title":"Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis","volume":"18","author":"Liu","year":"2004","journal-title":"Can J Gastroenterol"},{"issue":"8","key":"B142","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10067-011-1713-6","article-title":"Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute\/subacute interstitial pneumonia","volume":"30","author":"Kotani","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"11","key":"B143","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"B144","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1191\/0269215503cr572oa","article-title":"The effect of physical exercise following acute disease exacerbation in patients with dermato\/polymyositis","volume":"17","author":"Varj\u00fa","year":"2003","journal-title":"Clin Rehabil"},{"issue":"2","key":"B145","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/BOR.0b013e32834f19f5","article-title":"Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies","volume":"24","author":"Alexanderson","year":"2012","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"B146","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/acr.21684","article-title":"Exercise training in juvenile dermatomyositis","volume":"64","author":"Omori","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"B147","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/art.22996","article-title":"Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis","volume":"57","author":"Dastmalchi","year":"2007","journal-title":"Arthritis Care Res"},{"issue":"3","key":"B148","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11940-011-0119-8","article-title":"Immunotherapy of inflammatory myopathies: practical approach and future prospects","volume":"13","author":"Dalakas","year":"2011","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"B149","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Ann Neurol"},{"issue":"2","key":"B150","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","article-title":"Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study","volume":"61","author":"Lindberg","year":"2003","journal-title":"Neurology"},{"issue":"2 Suppl 1","key":"B151","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1212\/01.wnl.0000192258.32408.54","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology"},{"issue":"7","key":"B152","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","article-title":"A pilot randomized trial of oxandrolone in inclusion body myositis","volume":"58","author":"Rutkove","year":"2002","journal-title":"Neurology"},{"issue":"9","key":"B153","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","article-title":"Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis","volume":"57","author":"Muscle","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"B154","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","article-title":"Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis","volume":"63","author":"Muscle","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"B155","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"issue":"Suppl 3","key":"B156","doi-asserted-by":"publisher","first-page":"A164","DOI":"10.1136\/annrheumdis-2013-eular.527","article-title":"LB0002 safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, phase IIa proof-of-concept trial","volume":"72","author":"Machado","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"B157","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"B158","first-page":"621","article-title":"Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methylprednisolone pulse therapy","volume":"17","author":"Huang","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-1-4615-4857-7_54","article-title":"The effect of methylprednisolone pulse therapy in polymyositis\/dermatomyositis","volume":"455","author":"Bolosiu","year":"1999","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"B160","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s100670050032","article-title":"Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate","volume":"19","author":"Al-Mayouf","year":"2000","journal-title":"Clin Rheumatol"},{"issue":"7688","key":"B161","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0140-6736(71)80005-3","article-title":"Treatment of corticosteroid-resistant polymyositis with methotrexate","volume":"1","author":"Sokoloff","year":"1971","journal-title":"Lancet"},{"issue":"2","key":"B162","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/0003-4819-81-2-182","article-title":"Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy","volume":"81","author":"Metzger","year":"1971","journal-title":"Ann Intern Med"},{"issue":"10","key":"B163","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/archderm.115.10.1251","article-title":"Treatment of dermatomyositis with methotrexate and prednisone","volume":"115","author":"Giannini","year":"1979","journal-title":"Arch Dermatol"},{"issue":"6","key":"B164","first-page":"658","article-title":"Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis","volume":"9","author":"Cagnoli","year":"1991","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"B165","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/art.1780240107","article-title":"Prednisone and azathioprine for polymyositis: long-term followup","volume":"24","author":"Bunch","year":"1981","journal-title":"Arthritis Rheum"},{"issue":"3","key":"B166","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","article-title":"Azathioprine with prednisone for polymyositis. A controlled, clinical trial","volume":"92","author":"Bunch","year":"1980","journal-title":"Ann Intern Med"},{"issue":"3","key":"B167","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/1529-0131(199803)41:3392::AID-ART33.3.CO;2-O","article-title":"Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens","volume":"41","author":"Villalba","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"2","key":"B168","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/030097400750001897","article-title":"Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis","volume":"29","author":"Vencovsk\u00fd","year":"2000","journal-title":"Scand J Rheumatol"},{"issue":"12","key":"B169","first-page":"2855","article-title":"Cyclosporin A in the treatment of refractory adult polymyositis\/dermatomyositis: population based experience in 6 patients and literature review","volume":"27","author":"Qushmaq","year":"2000","journal-title":"J Rheumatol"},{"issue":"9166","key":"B170","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","article-title":"Tacrolimus in refractory polymyositis with interstitial lung disease","volume":"353","author":"Oddis","year":"1999","journal-title":"Lancet"},{"issue":"27","key":"B171","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"issue":"21","key":"B172","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N Engl J Med"},{"issue":"3","key":"B173","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","article-title":"Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy","volume":"44","author":"Majithia","year":"2005","journal-title":"Rheumatology"},{"issue":"1","key":"B174","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archderm.142.1.65","article-title":"Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis","volume":"142","author":"Edge","year":"2006","journal-title":"Arch Dermatol"},{"issue":"10","key":"B175","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/acr.20212","article-title":"Mycophenolate mofetil for interstitial lung disease in dermatomyositis","volume":"62","author":"Morganroth","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"B176","first-page":"1542","article-title":"Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases","volume":"27","author":"Gelber","year":"2000","journal-title":"J Rheumatol"},{"issue":"9","key":"B177","first-page":"1864","article-title":"Rituximab for refractory polymyositis: an open-label prospective study","volume":"34","author":"Mok","year":"2007","journal-title":"J Rheumatol"},{"issue":"9","key":"B178","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1002\/art.22856","article-title":"Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients","volume":"56","author":"Cooper","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"B179","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"B180","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"12","key":"B181","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies","volume":"50","author":"Mahler","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"B182","first-page":"982","article-title":"Successful IV pulse cyclophosphamide in refractory PM in 3 patients with SLE","volume":"17","author":"Kono","year":"1990","journal-title":"J Rheumatol"},{"issue":"1","key":"B183","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","article-title":"Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis","volume":"46","author":"Yamasaki","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"B184","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1212\/WNL.30.3.286","article-title":"Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis","volume":"30","author":"Niakan","year":"1980","journal-title":"Neurology"},{"issue":"2","key":"B185","doi-asserted-by":"publisher","first-page":"154162","DOI":"10.1002\/art.1780160204","article-title":"Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis","volume":"16","author":"Fries","year":"1973","journal-title":"Arthritis Rheum"},{"issue":"4","key":"B186","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","article-title":"Refractory polymyositis responding to infliximab: extended follow-up","volume":"43","author":"Labioche","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"B187","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000070852","article-title":"Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations","volume":"50","author":"Hengstman","year":"2003","journal-title":"Eur Neurol"},{"issue":"1","key":"B188","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000079547","article-title":"Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up","volume":"52","author":"Hengstman","year":"2004","journal-title":"Eur Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T22:16:57Z","timestamp":1656454617000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fneur.2016.00064\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,20]]},"references-count":188,"URL":"https:\/\/doi.org\/10.3389\/fneur.2016.00064","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,20]]}}}